How Predictive Analytics is Boosting Clinical Trials Efficiency?
Clinical trials are the backbone of modern medicine, responsible for bringing innovative, safe, and efficient treatments to market after rigorous testing and evaluation. However, the conventional process of conducting these trials has often been long, expensive, and fraught with inefficiencies¹. The advent of predictive analytics is reshaping the landscape of clinical trials, ushering in a new era of precision efficiency². This blog explores how predictive analytics is transforming clinical trials, from optimizing design and recruitment to predicting outcomes and reducing risks.
The Importance of Data Diversity to Enhance Clinical Trials Success
Medical advancement relies on clinical trials, which are essential for the development of safe and effective innovative treatments. However, the success and general applicability of these treatments heavily depend on the diversity of the participants involved¹⁻³. This blog explores the importance of achieving data diversity in clinical trials to enhance clinical trial results and achieve global health equity.
Matched tumor-normal sequencing: The preferred method for identifying somatic mutations driving tumorigenesis
Discover how matched tumor-normal sequencing can help clinical researchers detect the somatic origin of variants with certainty.
ECP Posters spotlight
We recently presented two posters at the European Congress of Pathology 2024, in Florence, Italy, in collaboration with Janssen Pharmaceutical, a Johnson & Johnson company. The posters provided real-world data insights on the genomic landscape of specific...
Case Study: Implementing comprehensive clinical exome analysis to support diverse applications at Henry Ford Health
See how Henry Ford Health enhanced their genetic testing by adopting exome sequencing for hereditary cancer, cystic fibrosis, and pharmacogenetics applications.
From Data to Decisions, Faster than Ever: Pioneering the future of precision medicine with the New Generation SOPHiA DDM™ Platform
In response to the emerging needs in global healthcare, SOPHiA GENETICS has just revealed the New Generation SOPHiA DDM™ Platform, aiming to stay at the forefront of precision medicine and address today the healthcare needs of tomorrow.
Guidelines Spotlight: ESMO urge NGS testing for additional advanced cancers
ESMO updated its recommendations for NGS in advanced cancers this year, urging broader use of NGS in additional cancer types and the inclusion of tumor-agnostic biomarkers.
Customer Spotlight: Laboratory of Genetics and Genomics, Cagliari
We recently spoke with Manuela Badiali, Rita Congiu, and Stefania Murru from the Laboratory of Genetics and Genomics, Microcitemico Pediatric Hospital – A. Cao, Cagliari, about how SOPHiA DDM™ RNAtarget Technology has helped them optimize their variant analysis workflow.
POSTER SPOTLIGHT: The Validation of a Homologous Recombination Deficiency Assay into Clinical Practice within the NHS
In this piece, we talked to the two presenters of the poster “The Validation of a Homologous Recombination Deficiency Assay into Clinical Practice within the NHS”, Elizabeth Ratsma, Pre-Registration Clinical Scientist – Cancer Genomics and Charlotte Flanagan, PhD, Innovation Lead, from The Royal Marsden NHS Foundation Trust. The poster was recently presented at the ESMO Gynaecological Cancers Congress 2024 in Florence, Italy. Read the full spotlight:
What Healthcare Institutions need to know about the IVDR transition
Let’s answer some of the most pressing questions about IVDR compliance in practice and explore how CE-IVD certified software solutions can help.
Customer Spotlight: Katherine Lafferty at Broad Clinical Labs
We recently sat down to talk with Katherine Lafferty, MS, CGC about how Alamut™ Visual Plus helps her overcome the variant interpretation challenges she encounters in her work as a variant analyst. Read our discussion.
ESGO Poster spotlight
Watch our poster spotlight interview, hosting Dr.Gardenia Vargas from Hospital del Mar in Barcelona, Spain discussing the poster presentation at ESGO 2024: “Multicenter Study To Validate And Implement SOPHiA DDM™ HRD Solution For Enhanced Molecular Diagnosis Of Ovarian Cancer.“
Article Spotlight: Machine learning-powered prediction of kidney cancer recurrence
Discover how we collaborated with the UroCCR network to develop a machine learning model that outperformed the predictive performance of most usual kidney cancer risk scores.
Article Spotlight: GIInger™ supports prediction of HRD and PARPi response from shallow genomic profiles
Discover how a deep learning algorithm, GIInger™, leverages low-coverage sequencing data to identify homologous recombination deficiency (HRD)-induced genomic instability.
Technical Note: Navigating overfitting during machine learning model development
We’re often asked how we avoid overfitting when developing predictive machine learning models for clinical research. This technical note explains how.
